KU Leuven (RA Clinical Research Group, Skeletal Biology and Engineering Research Centre, Department of Development and Regeneration, KU Leuven)
What is the optimal tapering strategy for rituximab in patients with Rheumatoid Arthritis: comparison of interval prolongation with disease activity guided dose reduction
Projet soutenu de Patrick Verschueren : Rituximab is an effective drug, but it is expensive and might be accompanied by an increased infection risk. Therefore, lowering the dose might be beneficial. According to the current reimbursement criteria, patients have to wait for a flare to be retreated, which might impact their quality of life. We plan to investigate if patients benefit from a systematic retreatment combined with a gradually reduced rituximab dose compared to rituximab interval prolongation in a randomised controlled trial.
Ont aussi bénéficié d'un soutien
Université Catholique de Louvain
Transcriptome study of individual cells isolated from synovial biopsies: can it help in the therapeutic management of early rheumatoid arthritis ?
Projet soutenu de Patrick Durez : Early diagnosis and therapeutic management of Rheumatoid arthritis (RA) are crucial. Early RA is treated with methotrexate (MTX) and after 3 mon…
Lire la suite
UZ Leuven/ KU Leuven
Clinical field tests as predictors of cardiorespiratory fitness and cardiometabolic risk in Psoriatic Arthritis.
Projet soutenu de Barbara Neerinckx : This project will study the potential of low cost, objective and highly generalisable clinical field tests, six minute walk and hand grip st…
Lire la suite